Sun Pharmaceutical Industries Limited announced UNLOXCYT?? (cosibelimab-ipdl) for Advanced Cutaneous Squamous Cell Carcinoma (aCSCC). UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.

UNLOXCYT offers a balanced treatment approach; the recently updated label now includes long-term data confirming durable efficacy and a proven tolerability profile. UNLOXCY T has a multifaceted mechanism of action (MOA); the first and only checkpoint inhibitor in aCSCC that helps restore the adaptive immune response and engages the innate immune system while preserving PD-L2 signaling. UNLOXC YT Support??

is focused on providing essential support for HCPs and aCSCC patients. Preclinical in vitro data may not translate to clinical outcomes. The U.S. Food and Drug Administration (FDA) recently approved an updated label for UNLOXCYT to reflect long-term follow-up data from the pivotal CK-301-101 clinical trial.

This study showed improvements in objective response rates (including more patients who achieved a complete response [CR) and duration of response. The safety data did not change from the original UNLOXCYT label. Many patients in the pivotal trial experienced durable responses with UNLOXCYT.

0.9% were Grade 3 (dermatologic only), with no Grade 4 imARs. Of particular note, no patients developed Grade 3 or 4 pneumonitis. Just 0.9% (two patients) experienced pneumonitis (Grade 2).

UNLOXCY T is available through a limited distribution network of authorized specialty distributors and one contracted specialty pharmacy. Healthcare professionals can visit UNLOXCYTPro.com for additional information. Sun Pharmaceuticals does not recommend the use of any particular distributor or specialty pharmacy.

For comprehensive support, UNLOXCYT Support is dedicated to supporting healthcare professionals and patients by providing resources for their journey on UNLOXCYT; Advise female patients not to breastfeed during treatment with UNLOXCY T and for 4 months after the last dose. ADVERSE REACTIONS. The most common adverse reactions (10%) were fatigue, musculoskeletal pain, rash, diarrhea, diarrhea, hypothyroidism, constipation, nausea, headache, prothyroidism, diarrhea, pripation, headache, procococococococolololololololite, and procococococolite, and the most common adverse reactions (10%).

The most common adverse reactions (10%) were fatigue, Musculoskeletal pain, nausea, headache, prococolite, and procolite. The most common adverse reactions were fatigue, musculosKEletal pain, diarrhea, hypothyroidist, constipation, nausea, nausea, headache, pracolite, procococolite, prococolite and prococolite.